Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chiroscience -- Ignore unavailable to you. Want to Upgrade?

To: Elayne Shochet Tatar who wrote (15)	1/7/1998 9:35:00 AM
From: James Reynolds	Read Replies (1) \| Respond to of 69

Elayne, I follow Chiroscience closely. Feel free to e-mail me if you have any specific questions.

To: Elayne Shochet Tatar who wrote (15)	1/21/1998 1:47:00 AM
From: A.J. Mullen	Read Replies (1) \| Respond to of 69

I sold this stock after they bought Darwin. I was disappointed at their dilution of their Chiral technology, and bought into Sepracor with the proceeds. Since then the price of Chiroscience has sunk with the rest of British Bio (the sector and the company). The sector in Britain is less mature than the US: they all fall when one company announces disappointing results. All British Biotechs are currently valued much lower than US companies They are expecting Chirocaine approval this year. The merger with Darwin seems a success. Their mass spec. technology for analyzing gene structure impresses me (a lay person). They are selling their services to other companies, while exploiting it themselves within their own niche, and are fast fledging into a fully developed Genomics company. I am back in.